Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Gilead SciencesGILD | Open-market sale10b5-1 plan | 06/15 | 06/16 | 3,000 sh | $125.40 | $376,200 | −1.7% | |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 06/15 | 06/16 | 3,000 sh3 trades | $123.92avg. | $371,771.6 | −2.4% | |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 06/01 | 06/02 | 15,000 sh3 trades | $131.46avg. | $1,971,870.5 | −2.4% | |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 05/15 | 05/18 | 3,000 sh | $132.27 | $396,810 | −1.7% | |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 05/15 | 05/18 | 28,000 sh4 trades | $131.29avg. | $3,676,146.86 | −18.2% | |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 04/28 | 04/29 | 10,000 sh2 trades | $129.16avg. | $1,291,621 | −1.6% | |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 04/15 | 04/16 | 3,000 sh | $140.96 | $422,880 | −1.7% | |
Johanna MercierChief Comm & Corp Aff Officer | Gilead SciencesGILD | Open-market sale10b5-1 plan | 04/15 | 04/16 | 3,000 sh | $140.96 | $422,880 | −2.3% |
Daniel Patrick O'DayChairman & CEO | Gilead SciencesGILD | Open-market sale10b5-1 plan | 03/27 | 03/30 | 10,000 sh | $136.82 | $1,368,200 | −1.5% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 03/16 | 03/17 | 3,000 sh | $144.23 | $432,690 | −1.6% | |
Johanna MercierChief Comm & Corp Aff Officer | Gilead SciencesGILD | Open-market sale10b5-1 plan | 03/16 | 03/17 | 3,000 sh | $144.23 | $432,690 | −2.2% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 02/27 | 03/02 | 10,000 sh3 trades | $144.79avg. | $1,447,884.66 | −1.5% | |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 02/17 | 02/18 | 3,000 sh | $154.43 | $463,290 | −1.8% | |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 02/17 | 02/18 | 28,000 sh3 trades | $154.44avg. | $4,324,186.35 | −18.9% | |
Daniel Patrick O'DayChairman & CEO | Gilead SciencesGILD | Open-market sale10b5-1 plan | 02/05 | 02/06 | 115,640 sh | $150.00 | $17,346,000 | −15.9% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 01/28 | 01/29 | 10,000 sh2 trades | $139.89avg. | $1,398,877.6 | −1.8% | |
Daniel Patrick O'DayChairman & CEO | Gilead SciencesGILD | Open-market sale10b5-1 plan | 01/23 | 01/26 | 115,640 sh | $135.00 | $15,611,400 | −16.9% |
Jeffrey BluestoneDirector | Gilead SciencesGILD | Open-market sale10b5-1 plan | 01/20 | 01/21 | 5,000 sh | $123.50 | $617,500 | −35.9% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 01/15 | 01/16 | 3,000 sh | $124.31 | $372,930 | −2.0% | |
Johanna MercierChief Commercial Officer | Gilead SciencesGILD | Open-market sale10b5-1 plan | 01/15 | 01/16 | 3,000 sh | $124.31 | $372,930 | −2.8% |